Safety of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial

#1538

Introduction: Dose escalation (or interval reduction) of somatostatin analogs (SSAs) is a rather common strategy for patients (pts) with progressive metastatic neuroendocrine tumors (NETs). However, to date, no systematic prospective studies have been carried out to evaluate safety and efficacy of this treatment schedule in NETs.

Aim(s): Evaluate high doses of lanreotide (LAN) in progressive (PD) NETs.

Materials and methods: A multicenter, prospective, open label, single arm phase II study with LAN ATG (180 mg/28 days for 12 months) has been completed in 35 pts with PD NET under standard maximal doses of SSAs. Primary endpoint was safety, while secondary was efficacy.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Albertelli M, Campana D, Faggiano A, Spada F, Baldelli R,

Keywords: high doses lanreotide safety ,